



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT
WX0000003039 M 12/05/1988 34 Y

Referral Testing

Collected: 11/23/2021 08:36 Received: 11/23/2021 08:36

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: HIV-1 Genotype (RTI, PI, Integrase Inhibitors), NOT DETECTED, QCR

The method used in this test is RT-PCR and sequencing of the HIV-1 polymerase gene.

The phrases 'resistance predicted' and 'probable or emerging resistance' refer to the application of the interpretive rules. The FDA has not reviewed all of the interpretive rules used by the laboratory to predict drug resistance. FDA may not currently recognize some of the HIV gene mutations reported as predictive of drug resistance, but the laboratory considers these mutations to be associated with resistance to anti-viral drugs based on current clinical or scientific studies.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Test Performed at:
Quest Diagnostics Infectious Disease, Inc.
33608 Ortega Highway
San Juan Capistrano, CA 92675-2042 H J Batterman MD

Table with 3 columns: Test Name, Result, QCR. Rows include: Value of Last Viral Load (45), Date Viral Load Collected (11/11/2021), Raltegravir Resistance (NOT PREDICTED), Elvitegravir Resistance (NOT PREDICTED), Dolutegravir Resistance (NOT PREDICTED), Bictegravir Resistance (NOT PREDICTED), Cabotegravir Resistance (NOT PREDICTED).

The Quest Diagnostics September 2021 Interpretation Algorithm

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT
WX0000003039 M 12/05/1988 34 Y

Referral Testing

Collected: 11/23/2021 08:36 Received: 11/23/2021 08:36

<u>Test Name</u>	<u>Result</u>	<u>Flag</u>	<u>Ref-Ranges</u>	<u>Units</u>	<u>Site</u>
------------------	---------------	-------------	-------------------	--------------	-------------

The method used in this test is RT-PCR and sequencing of the HIV-1 integrase gene. The phrases 'resistance predicted' and 'probable or emerging resistance' refer to the application of the interpretive rules. The FDA has not reviewed all of the interpretive rules used by the laboratory to predict drug resistance. FDA may not currently recognize some of the HIV gene mutations reported as predictive of drug resistance, but the laboratory considers these mutations to be associated with resistance to anti-viral drugs based on current clinical or scientific studies.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

For more information on this test, go to:
<http://education.questdiagnostics.com/faq/FAQ135>
(This link is being provided for informational/educational purposes only.)

Test Performed at:
Quest Diagnostics Infectious Disease, Inc.
33608 Ortega Highway
San Juan Capistrano, CA 92675-2042 H J Batterman MD

Reported Date: 11/23/2021 08:39 HVGII

Performing Site:

QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

D123000000 Ordered By: CLIENT CLIENT
WX0000003039 WX00000000001595
Printed D&T: 11/30/23 14:59

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1
PAGE 2 OF 2